Debate: Treatment for Resectable Pancreatic Cancer? - Neo-Adjuvant Chemotherapy

Earn CME for related activities: hmpeducation.com/
In this webcast from the '2019 ESMO World Congress on Gastrointestinal Cancer', Dr. Thomas Seufferlein argues in favor of the use of neo-adjuvant chemotherapy for the treatment of resectable pancreatic cancer.

[@khaliddurrani6432]

You mean to say that neo adj chemo could also help in the selection of the patients for potentially curative surgery. The argument being that Patients who progress on folfrinox are less likely to benefit from resection. The only other benefit of neo-adj treatment is a higher chance of R0 resection and a potential to take care of the micro mets.
On the contrary neo-adj treatment may delay surgery in operable cases,the only potentially curative treatment and disease progression or toxicity may delay resection and result in inoperability.
Moreover neo-adj treatment requires stents to relieve jaundice and this is associated with increased peri-op morbidity.

[@delinquense]

Intuitively, I would think surgery followed by chemo would lead to the best outcomes in MOST circumstances.... but hey, what do I know. Get the majority out as soon as possible, survey the damage and follow up with chemo to hopefully deal with any systemic stragglers left behind.
What if a patient was eligible for surgery but opted for neo adjuvant chemo but then found out several months later that the chemo was not effective?